GSMA
10.9.2019 04:02:10 CEST | Business Wire | Press release
The GSMA today announced the first speakers for the 2019 Mobile 360 Series – Digital Societies conference, which will take place 24-26 September at JW Marriott Hotel Kuala Lumpur, Malaysia. The event is supported by the Malaysian Communications and Multimedia Commission (MCMC) and also the Malaysia Convention and Exhibition Bureau (MyCEB). Host sponsor for the event is Axiata with other event sponsors including Fiberhome (Headline Sponsor), Edotco, Gigabyte, Huawei and Telepin (Industry Sponsors), as well as Arm (eSim Supporting Sponsor).
“We are excited to bring the Mobile 360 – Digital Societies event to Malaysia for the first time as mobile technology is no doubt playing a pivotal role in driving economic development in the Asia Pacific Region,” said, John Hoffman, CEO, GSMA Ltd. “This three-day event will provide a perfect platform for stakeholders to share their experiences and expand the positive impact of mobile throughout this vibrant and diverse region.”
Keynote Speakers
At the event, industry-leading speakers will shine a light on APAC innovation examining how developments in these core areas are powering digital transformation across the region. Speakers confirmed to present at Mobile 360 – Digital Societies include:
- Gobind Singh Deo, Minister of Communication and Multimedia, Malaysia
- YBrs. Encik Al-Ishsal Ishak, Chairman, Malaysian Communications and Multimedia Commission
- Sok Puthyvuth, Secretary of State, Cambodia MPTC
- Tony Fernandes, CEO, AirAsia Group
- Dr Hans Wijayasuriya, Corporate EVP and Regional CEO, South Asia, Axiata
- Loke Hwee Wong, VP, APAC, Boku
- Teddy Oetomo, CSO, Bukalapak
- Michael Patent, CEO, Culture Group
- Albern Murty, CEO, Digi Telecommunications
- Suresh Sidhu, CEO, edotco
- Wang Xiaofei, CMO, Fiberhome
- Louise Easterbrook, CFO, GSMA
- Khoo Yuen Hing, CTO, Huawei
- Masayoshi Sakai, Counsellor, Information-technology Promotion Agency, Japan
- Sohee Shin, SVP, Global Business Unit and Global Alliance Division, KT
- Gokhan Ogut, CEO, Maxis Broadband Sdn Bhd
- Maya Arvini, CCO, Qlue
- Takeshi Fukuizumi, Head of Fintech and Blockchain, Softbank
- Foong Yuh Wen, CEO and Founder, Sushivid
- Anthony Socci, President and General Manager, APAC, Synchronoss
- Vince Kadar, CEO, Telepin
- Brad Jones, CEO, Wave Money
- Kaspar Tiri, Co-Founder, Wolf 3D
- David An, CTO, ZTE Group Asia
The full conference agenda is available at https://www.mobile360series.com/digital-societies/agenda/ .
In addition to the keynotes, a series of in-depth workshops and sessions will allow a deeper dive into the industry’s most complex challenges looking at topics such as Forging Digital Societies Through Digital Platforms , Building Simple, Clear and Fast Public Services and 5G and Digitalisation . Mobile 360 – Digital Societies will examine the attributes that contribute to a successful digital society. Focusing on the digital platforms enabling new and innovative services, the event highlights the key elements that define a successful digital society including citizenship, commerce, identity, lifestyle and connectivity, and how developments in these key areas can lead to gains for society as a whole.
Women4Tech Leaders Reception
Mobile 360 – Digital Societies will host the first Women4Tech Leaders Reception in APAC on 24 September 2019 from 5:30pm-7:30pm. The event will stimulate discussion on the benefits of encouraging gender diversity in the tech industry and addressing what can be done about the current gender gap through education and public policy. It will also look at ways to promote gender diversity culture in business organisations.
Registration for Women4Tech Leaders Reception is available here: www.mobile360series.com/digital-societies/agenda/apply-to-attend-workshop/#contact
Registration for Mobile 360 – Digital Societies is now open; individuals wishing to attend should visit www.mobile360series.com/digital-societies/attend/attendee-registration/ . For further information on Mobile 360 – Digital societies, please visit: www.mobile360series.com/digital-societies/overview/ . Further information on the entire Mobile 360 Series of events is available at www.mobile360series.com/ . Follow developments and updates on Mobile 360 Series (#mobile360) on Twitter @GSMA and on Facebook www.facebook.com/Mobile360Series .
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom